Suk-Joon Chang

Suk-Joon Chang

Ajou University

H-index: 31

Asia-South Korea

About Suk-Joon Chang

Suk-Joon Chang, With an exceptional h-index of 31 and a recent h-index of 21 (since 2020), a distinguished researcher at Ajou University, specializes in the field of Obstetrics and Gynecology, Gynecologic Oncology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Average log change rate of pretreatment squamous cell carcinoma antigen after concurrent chemoradiotherapy in stage IIIC1 cervical squamous cell carcinoma

Extra-abdominal cytoreductive techniques in ovarian cancer: how far can (should) we go?

253 Rationale and study design of the KOV-HIPEC-04: a phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery …

252 Rationale and study design of the KOV-HIPEC-02 trial: a randomized, multicenter, open-label phase III trial of hyperthermic intraperitoneal chemotherapy in platinum …

312 Safety and efficacy of laparoscopic or robot-assisted radical surgery using an endoscopic stapler for inhibiting tumour spillage of cervical malignant neoplasm (SOLUTION …

Effect of high-dose polymeric nanoparticle micellar paclitaxel on improved progression-free survival in patients with optimally resected stage III or IV high-grade carcinoma of …

Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines

Surgery for Recurrent Epithelial Ovarian Cancer

Suk-Joon Chang Information

University

Position

School of Medicine

Citations(all)

3715

Citations(since 2020)

2016

Cited By

2583

hIndex(all)

31

hIndex(since 2020)

21

i10Index(all)

76

i10Index(since 2020)

53

Email

University Profile Page

Google Scholar

Suk-Joon Chang Skills & Research Interests

Obstetrics and Gynecology

Gynecologic Oncology

Top articles of Suk-Joon Chang

Average log change rate of pretreatment squamous cell carcinoma antigen after concurrent chemoradiotherapy in stage IIIC1 cervical squamous cell carcinoma

Scientific Reports

2024/4/15

Oyeon Cho
Oyeon Cho

H-Index: 9

Suk-Joon Chang
Suk-Joon Chang

H-Index: 21

Extra-abdominal cytoreductive techniques in ovarian cancer: how far can (should) we go?

2024/3/1

Suk-Joon Chang
Suk-Joon Chang

H-Index: 21

253 Rationale and study design of the KOV-HIPEC-04: a phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery …

2024/3/1

252 Rationale and study design of the KOV-HIPEC-02 trial: a randomized, multicenter, open-label phase III trial of hyperthermic intraperitoneal chemotherapy in platinum …

2024/3/1

312 Safety and efficacy of laparoscopic or robot-assisted radical surgery using an endoscopic stapler for inhibiting tumour spillage of cervical malignant neoplasm (SOLUTION …

2024/3/1

Effect of high-dose polymeric nanoparticle micellar paclitaxel on improved progression-free survival in patients with optimally resected stage III or IV high-grade carcinoma of …

Frontiers in Oncology

2024

Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines

Journal of Gynecologic Oncology

2024/1

Suk-Joon Chang
Suk-Joon Chang

H-Index: 21

Yun Hwan Kim
Yun Hwan Kim

H-Index: 13

Surgery for Recurrent Epithelial Ovarian Cancer

2024/1

Suk-Joon Chang
Suk-Joon Chang

H-Index: 21

PR031/# 378 A predictive model for lymph node metastasis using a tumor location in presumed early-stage endometrioid endometrial cancer patients

2023/11/1

Jimin Lee
Jimin Lee

H-Index: 1

Suk-Joon Chang
Suk-Joon Chang

H-Index: 21

PO001/# 381 Is minimally invasive surgery safe for cervical cancer patients with a diameter of less than 2 cm?(MISAFE): gynecologic oncology research investigators collboration …

2023/11/1

Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with advanced-stage ovarian cancer who had received neoadjuvant chemotherapy

JAMA surgery

2023/11/1

Impact of warm saline irrigation, hyperthermic intraperitoneal chemotherapy on postoperative pain in primary ovarian cancer from the KOV-HIPEC-01 randomized trial

Gynecologic Oncology

2023/10/1

Ji Hyun Kim
Ji Hyun Kim

H-Index: 36

Suk-Joon Chang
Suk-Joon Chang

H-Index: 21

Risk factors for the failure of first‐line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators …

Cancer Medicine

2023/10

Risk factor for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic oncology research investigators coLLborAtion …

Gynecologic Oncology

2023/9/1

Comparison of Survival of Radical hysterectomy and chemoradiation for cervical cancer with an absence of Parametrial involvement and suspicious lymph node metastasis (SURPRISE …

Gynecologic Oncology

2023/9/1

Endometrial surveillance strategy for detection of tamoxifen-related uterine cancers (2235)

Gynecologic Oncology

2023/9/1

Jimin Lee
Jimin Lee

H-Index: 1

Suk-Joon Chang
Suk-Joon Chang

H-Index: 21

Tumor location as a risk factor for lymph node metastasis in presumed early-stage endometrioid endometrial cancer patients (1225)

Gynecologic Oncology

2023/9/1

Jimin Lee
Jimin Lee

H-Index: 1

Suk-Joon Chang
Suk-Joon Chang

H-Index: 21

The oncologic and pregnancy outcomes of fertility-sparing hormonal treatment in patients with early endometrioid endometrial cancer of all grade: A Korean multicenter …

Gynecologic Oncology

2023/9/1

Laparoscopic versus laparotomic surgery in the treatment of stage I adult granulosa cell and Sertoli-Leydig cell tumors (1224)

Gynecologic Oncology

2023/9/1

Jimin Lee
Jimin Lee

H-Index: 1

Suk-Joon Chang
Suk-Joon Chang

H-Index: 21

Is minimally invasive radical surgery safe for patients with cervical cancer≤ 2 cm in size?(MISAFE): Gynecologic Oncology Research Investigators coLLborAtion study (GORILLA-1003)

Gynecologic Oncology

2023/9/1

See List of Professors in Suk-Joon Chang University(Ajou University)